Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NYESO-1c259 T cells · 1 trial · 1 indication
Number of Participants with Adverse Events related to study treatment
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells. |
| Name | Type | Description |
|---|---|---|
| NYESO-1c259 T cells | BIOLOGICAL | Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion. |
Inclusion Criteria: * Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with refractory or platinum resistant disease and/or have received ≥ 2 lines of chemotherapy * Age ≥ 18 years of age * No significant immunodeficiency * Have been informed of ...
Top 20 of 63 competitors
NYESO-1c259 T cells are an investigational cell therapy being studied in ovarian cancer. They are a biologic product developed by Adaptimmune Therapeutics PLC. The program has been evaluated in a single Phase 1/2 clinical trial conducted in the United States that enrolled 9 participants and is now completed.
NYESO-1c259 T cells have been studied for the treatment of ovarian cancer. The clinical work in this program focused on patients with ovarian cancer, with trial participants aged 18 years and older. The therapy remains investigational and is not an approved treatment for ovarian cancer or any other indication.
NYESO-1c259 T cells are being developed by Adaptimmune Therapeutics PLC, which trades under the ticker ADAPY. The company is the sponsor behind the ovarian cancer cell therapy program, which has completed one Phase 1/2 clinical trial in the United States.
NYESO-1c259 T cells are in Phase 1/2 development. The program's single clinical trial, NCT01567891, was a Phase 1/Phase 2 study in ovarian cancer that has been completed. NYESO-1c259 T cells are investigational and are not FDA approved.
NYESO-1c259 T cells have been evaluated in one clinical trial, NCT01567891, titled CT Antigen TCR-redirected T Cells for Ovarian Cancer. The Phase 1/Phase 2 study was conducted in the United States, enrolled 9 participants, used an uncontrolled design, and is completed.